Scholarlink

Objective <p>We investigated profiles of clinical symptoms and kinetic α-synuclein seed amplification assay (αSyn-SAA) parameters in skin across the spectrum of Lewy body disease by comparing normosmic healthy controls (HC), individuals with idiopathic olfactory dysfunction (iOD), and dementia with Lewy bodies (DLB) patients.</p> Methods <p>In this cross-sectional, case–control study, we included 49 αSyn-SAA-negative HC, 18 αSyn-SAA-positive iOD, and 25 αSyn-SAA-positive DLB patients. αSyn-SAA was performed on olfactory mucosa swabs and skin biopsies. Only the skin-derived kinetic parameters were explored for comparative kinetic analysis (13 iOD and 24 DLB). Clinical assessments included the Sniffin’ Sticks 16 for olfaction, Montreal Cognitive Assessment (MoCA), REM Sleep Behavior Disorder Single-Question (RBD1Q), and the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) I–III.</p> Results <p>We observed a stepwise increase in symptoms across groups from HC to iOD to DLB, measured by MoCA (<i>p</i> &lt; 0.05) and MDS-UPDRS I, II, III (<i>p</i> &lt; 0.001). Participants with iOD and DLB did not differ in olfactory function (mean [SD]: 6.5 [2.4] vs. 6.0 [2.5], <i>p</i> = 0.51). Accelerated αSyn seeding kinetics, particularly shorter time to 50% of maximal fluorescence, were detected in DLB vs iOD (median hours [interquartile range] 17 [15–20] vs 14 [13–16], <i>p</i> = 0.017), achieving a classification accuracy of 74% (95% CI 57–91), and correlated with number of symptoms related to DLB without and with adjusting for age and sex (<i>p</i> = 0.002, <i>R</i><sup>2</sup> = 0.605).</p> Conclusions <p>These findings delineate the Lewy body symptom profile in iOD positioning iOD as a prodromal stage in which peripheral αSyn aggregation kinetics can be detected.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlating symptoms and skin α-synuclein seeding parameters in olfactory dysfunction and Lewy body dementia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月16日

查看全文
  • Oskar H. McWilliam,
  • Remarh Bsoul,
  • Aušrinė Areškevičiūtė,
  • Ida S. B. Andersen,
  • Marie Bruun,
  • Christian von Buchwald,
  • Steen G. Hasselbalch,
  • Eva L. Lund,
  • Christian K. Pedersen,
  • Anja H. Simonsen,
  • Gunhild Waldemar,
  • Kasper Aanæs,
  • Kristian S. Frederiksen

摘要

Objective

We investigated profiles of clinical symptoms and kinetic α-synuclein seed amplification assay (αSyn-SAA) parameters in skin across the spectrum of Lewy body disease by comparing normosmic healthy controls (HC), individuals with idiopathic olfactory dysfunction (iOD), and dementia with Lewy bodies (DLB) patients.

Methods

In this cross-sectional, case–control study, we included 49 αSyn-SAA-negative HC, 18 αSyn-SAA-positive iOD, and 25 αSyn-SAA-positive DLB patients. αSyn-SAA was performed on olfactory mucosa swabs and skin biopsies. Only the skin-derived kinetic parameters were explored for comparative kinetic analysis (13 iOD and 24 DLB). Clinical assessments included the Sniffin’ Sticks 16 for olfaction, Montreal Cognitive Assessment (MoCA), REM Sleep Behavior Disorder Single-Question (RBD1Q), and the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) I–III.

Results

We observed a stepwise increase in symptoms across groups from HC to iOD to DLB, measured by MoCA (p < 0.05) and MDS-UPDRS I, II, III (p < 0.001). Participants with iOD and DLB did not differ in olfactory function (mean [SD]: 6.5 [2.4] vs. 6.0 [2.5], p = 0.51). Accelerated αSyn seeding kinetics, particularly shorter time to 50% of maximal fluorescence, were detected in DLB vs iOD (median hours [interquartile range] 17 [15–20] vs 14 [13–16], p = 0.017), achieving a classification accuracy of 74% (95% CI 57–91), and correlated with number of symptoms related to DLB without and with adjusting for age and sex (p = 0.002, R2 = 0.605).

Conclusions

These findings delineate the Lewy body symptom profile in iOD positioning iOD as a prodromal stage in which peripheral αSyn aggregation kinetics can be detected.